graft-versus-host disease. [2] [3] [4] [5] [6] HHV-6B infection generally occurred in 30%-40% of HSCT recipients, and the virus was detected at 2-4 weeks after transplant that was earlier than cytomegalovirus (CMV) infection. [7] [8] [9] HHV-6B infection occurring concurrently with engraftment is a significant characteristic finding of post-transplant viral infection.
Although the frequency and timing of HHV-6B infection in
HSCT recipients is well established, the association between HHV-6B infection and its clinical manifestations in HSCT recipients remains unclear. In our institute, both virus isolation and realtime polymerase chain reaction (PCR) have been used to monitor active HHV-6B infection in HSCT recipients. 8 HHV-6B viremia and DNAemia were detected at 2-4 weeks after transplant and resolved without any specific antiviral treatment. In some recipients, we noticed that HHV-6B viremia and DNAemia persisted for, or emerged after, 60 days post transplant. Since most of the previous studies have focused on HHV-6 infection around 4-6 weeks after transplantation, 2, 8, 10, 11 information on late-phase HHV-6 infection 60 days after transplantation is insufficient. Given that HHV-6B reactivation frequently occurred in critically ill patients who were admitted to the intensive care unit, [12] [13] [14] we investigated whether late-phase HHV-6B infection occurring after 60 days post-transplant was associated with serious outcomes and mortality in pediatric HSCT recipients.
| MATERIAL S AND ME THODS

| Subjects and samples
All patients received HSCT at Nagoya University Graduate School infection weekly for at least 60 days after HSCT (median sampling time was 73 days after transplantation; IQR: 62-83.5 days).
Twenty-four cases were excluded from the analyses: 1 case of inherited chromosomally integrated HHV-6 (iciHHV-6), 4 cases of second HSCT, and 19 cases of autologous transplant recipients ( Figure 1 ). Clinical information was collected from medical records. Grades, organ types (skin, gastrointestinal, and liver), and stages of acute graft-versus-host disease (GVHD) were categorized as previously described. 15 Chronic GVHD was categorized according to the National Institutes of Health consensus guidelines. 16 
| Monitoring of HHV-6B infection
Ethylenediaminetetraacetic acid-treated peripheral blood samples were collected weekly from the HSCT recipients. Peripheral blood mononuclear cells (PBMCs) were used for virus isolation.
DNA was extracted from 200 μL of whole-blood samples using the QIAamp DNA Blood Mini kit (Qiagen, Hilden, Germany).
Real-time PCR was carried out to measure HHV-6B DNA load in whole-blood samples. Patients were identified as having latephase HHV-6B infection if either positive viral isolation or more than 1 × 10 4 copies/mL of viral DNA were detected after 60 days post-transplant.
| Isolation of HHV-6B
The method for HHV-6 isolation was as previously described. 17 PBMCs were co-cultured with pre-stimulated cord blood mononuclear cells.
Positive cultures were confirmed by indirect immunofluorescent staining with the HHV-6B-specific monoclonal antibody (OHV-3). 
| Real-time quantitative PCR assay
The PCR primers and probe for HHV-6 were selected from the U31 gene (large tegument protein). The upstream primer was 5′TTTGCAGTCATCACGAT-CGG-3′, and downstream primer was 5′-AGAGCGACAAATTGGAGGTTTC-3′. A fluorogenic probe (5′-A GCCACAGCAGCCATCTACATCTGTCAA-3′) was located between the primers. The PCR reaction was performed using a TaqMan PCR kit (PE Applied Biosystems, Foster City, CA, USA) as previously described. 18 HHV-6 species in the HHV-6 DNA-positive samples was determined based on restriction fragment length polymorphism analysis as previously described. 19 If more than 1 × 10 5 copies/mL of viral DNA in whole blood persisted, HHV-6 DNA loads in hair follicles and buccal mucosa swab samples were measured by real-time PCR analysis to confirm chromosomally integrated HHV-6.
| Statistical analysis
The cumulative incidence of HHV-6B infection was conducted by using GraphPad Prism 5 (GraphPad Software, La Jolla, CA, USA Multivariable logistic models were used to determine independent risk factors for late-phase HHV-6B infection. Then, the propensity score was calculated using multivariable logistic regression with the significant risk factors for late-phase HHV-6B infection. Inverse probability-weighted multivariable logistic regression analysis was performed to assess the association of late-phase HHV-6B infection with mortality after sequentially adjusting for potential prognostic factors (ie, acute GVHD, chronic GVHD, and relapse). 20 Finally, we analyzed the association between late-phase HHV-6B infection and relapse, which was considered as a mediating factor using Fisher's exact test. Statistical significance was defined as P < .05. JMP version 12.2 (SAS Institute, Cary, NC, USA) was used for analyses.
| Ethics approval
This study was approved by the Ethical Review Board Human Studies at Fujita Health University (Accession number 321, approved on November 6, 2015). Written informed consents were obtained from all of the participants or guardians of the subjects.
| RE SULTS
| Patient characteristics and HHV-6B infection after HSCT
The characteristics of the included 89 recipients are shown in Table 1 .
Hematologic malignancy included acute lymphoblastic leukemia (n = 19), acute myeloid leukemia (n = 9), malignant lymphoma (n = 3), myelodysplastic syndrome (n = 13), chronic myeloid leukemia (n = 3), and chronic active Epstein-Barr virus (EBV) infection (n = 4).
Others included aplastic anemia (n = 32), primary immunodeficiency (n = 5), and familial hemophagocytic lymphohistiocytosis (n = 1). A total of 977 whole blood samples were collected from the subjects 
| Risk factors for late-phase HHV-6B infection
Nine (75%) of the 12 recipients with late-phase HHV-6B infection were older than 10 years compared with 41/89 (46%) who were older than 10 years (P = .031). Ten (83%) of the 12 recipients with the late-phase HHV-6B infection had hematological malignancy as an underlying disease. The percentage of recipients with hematologic malignancies was slightly higher in recipients with late-phase HHV-6B infection than in other recipients, but it was not statistically significant (P = .05). Although 9/12 (75%) recipients with late- (Table 2 ).
| Late-phase HHV-6B infection and overall mortality
Of the 89 recipients, 15 cases had fatal outcomes (17%). Median time of death in 15 fatal cases was 409 days (IQR: 150-918 days).
Five of the 12 cases with late-phase HHV-6B infection had fatal outcomes (42%), and late-phase HHV-6B infection was significantly associated with overall mortality in the univariable analysis (OR: 3.3, 95% CI: 1.5/7.5, P = .0042). Inverse probability-weighted multivariable logistic models revealed that late-phase HHV-6B infection was significantly associated with overall mortality (OR: 4.2, 95% CI: 1.7/11.0, P = .0012) independent of acute GVHD (OR: 2.8, 95% CI: 1.1/7.6, P = .0341) ( Table 3 , Model 1). Since relapse was considered to be the most important risk factor for overall mortality, and as a mediating factor for late-phase HHV-6 infection, this risk factor was added to model 1 analysis to see the possible effect.
As expected, only relapse was an independent risk factor for overall mortality ( F I G U R E 2 Cumulative incidence curves of late-phase HHV-6B infection.
The first HHV-6B infection was defined as the first detection of HHV-6B DNA (>10 000 copies/mL in whole blood) and/ or viral isolation after HSCT Table 4 
| D ISCUSS I ON
In this study, real-time PCR in combination with virus isolation were We identified risk factors for late-phase HHV-6B infection.
Hematological malignancy and unrelated donor transplantation
were previously identified as risk factors for HHV-6B infection early after transplantation. Given that only a limited number of studies have focused on HHV-6 infection beyond 60 days post-transplant, the clinical features of late-phase HHV-6B infection remain unclear. 21, 22 It has been suggested that post-transplant HHV-6B infection was associated with higher mortality 22 and non-relapse mortality. 2, 10 In this study, as the number of cases with late-phase HHV-6B infection was small in comparison with the number of cases without the viral infection, the propensity score for late-phase HHV-6B infection was calculated and inverse probability-weighted analysis was TA B L E 3 Inverse probability of late-phase HHV-6B infection weighted multivariable logistic regression analysis for mortality used to eliminate the bias caused by the small number of cases.
